news
EMA validates MAA for Pfizer’s Ibrance
21 August 2015 | By Victoria White
The EMA has validated for review a MAA for Ibrance in combination with endocrine therapy for the treatment of HR+/HER2- metastatic breast cancer...
List view / Grid view
Pfizer
news
CMA accuses Pfizer and Flynn Pharma of overcharging
6 August 2015 | By Victoria White
The CMA has accused Pfizer and Flynn Pharma of charging excessive and unfair prices in the UK for phenytoin sodium capsules, an anti-epilepsy drug...
news
EC approves Pfizer’s pending acquisition of Hospira
5 August 2015 | By Victoria White
The ECs has approved Pfizer’s pending acquisition of Hospira - a transaction that will greatly expand Pfizer's sterile injectable pharmaceuticals portfolio...
news
Pfizer and Synthon enter commercialisation agreement
4 August 2015 | By Victoria White
Pfizer and Synthon have entered into an agreement whereby Pfizer has acquired the exclusive commercialisation rights in the US to glatiramer acetate...
news
Serious adverse events rare in healthy volunteers participating in Phase I trials
7 July 2015 | By Victoria White
A new study has found that less than 1% of 11,000 healthy volunteers who participated in 394 Phase I trials for new drugs experienced serious complications...
news
Pfizer begins Phase 2b study of S. aureus vaccine in adults undergoing elective spinal fusion surgery
7 July 2015 | By Victoria White
The first patients have been enrolled in a Phase 2b clinical trial of Pfizer’s S. aureus vaccine in adults undergoing elective spinal fusion surgery...
news
FSA accepts for review NDA for a once daily formulation of Xeljanz modified release tablets
3 July 2015 | By Victoria White
The FDA has accepted for review Pfizer’s new drug application (NDA) for Xeljanz (tofacitinib citrate) 11 mg once daily modified release tablets...
news
Pfizer announces enrolment of first patient in Phase 3 trial in sickle cell disease
24 June 2015 | By Victoria White
The first patient has been enrolled in Pfizer’s RESET study of rivipansel for the treatment of vaso-occlusive crisis in patients with sickle cell disease...
news
Results of Phase 3 study of andexanet alfa presented at ISTH 2015
22 June 2015 | By Victoria White
Full results from the second part of a Phase 3 trial evaluating the safety and efficacy of andexanet alfa as a reversal agent of Eliquis have been announced...
news
Pfizer to acquire GSK meningitis vaccines
22 June 2015 | By Victoria White
Pfizer has entered into an agreement with GlaxoSmithKline to acquire its quadrivalent meningitis ACWY vaccines, Nimenrix and Mencevax, for $130 million...
news
Phase 3 study evaluating Pristiq in paediatric patients with major depressive disorder fails to meet its primary objective
12 June 2015 | By Victoria White
Top line results from a Phase 3 study evaluating Pristiq in paediatric patients with Major Depressive Disorder (MDD) have been announced...
news
RAPAMUNE becomes first FDA-approved treatment for lymphangioleiomyomatosis (LAM)
1 June 2015 | By Victoria White
The US Food and Drug Administration (FDA) has approved Pfizer’s RAPAMUNE (sirolimus) in the US for the treatment of lymphangioleiomyomatosis (LAM)...
news
Palbociclib more than doubled progression-free survival in Phase 3 trial for patients with HR+, HER2- metastatic breast cancer
1 June 2015 | By Victoria White
Results from a Phase 3 study demonstrate that palbociclib significantly extended progression-free survival in women with HR+HER2- metastatic breast cancer...
news
Pfizer announces initial results of its rheumatoid arthritis NarRAtive patient survey
28 May 2015 | By Victoria White
Pfizer has announced initial results of its global NarRAtive survey of more than 3,600 adults with rheumatoid arthritis in 13 countries...
news
Pfizer acquires minority interest in AM-Pharma and secures option to acquire company
12 May 2015 | By Victoria White
Pfizer has acquired a minority equity interest in AM-Pharma and secured an exclusive option to acquire the remaining equity in the company...
